Aβ and tau toxicities in Alzheimer's are linked via oxidative stress-induced p38 activation: Protective role of vitamin E

Redox Biology

Volumn 2, Issue 1, 2014, Pages 873-877

  Giraldo, E ^a   Lloret, A ^a   Fuchsberger, T ^a   Vina J ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antioxidant; Beta amyloid; P p38; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; TAU PROTEIN; TROLOX C; PROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FETUS; HIPPOCAMPUS; IN VIVO STUDY; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; MALE; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; TOXICITY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MALE; MICE; MICE, TRANSGENIC; NEURONS; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTECTIVE AGENTS; RATS; TAU PROTEINS; VITAMIN E;

EID: 84904093190     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.03.002     Document Type: Article

References (25)

1. Ashwell J.D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nature Reviews. Immunology 2006, 6:532-540. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1038/nri1865.
2. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X., Pye Q.N., Stewart C.A., Geddes J., Markesbery W.R. p38 kinase is activated in the Alzheimer's disease brain. Journal of Neurochemistry 1999, 72:2053-2058. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1046/j.1471-4159.1999.0722053.
3. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Localization of active forms of c-Jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. Journal of Alzheimer's Disease 2001, 3:41-48. http://www.ncbi.nlm.nih.gov/pubmed/.
4. Sun A., Liu M., Nguyen X.V., Bing G. P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Experimental Neurology 2003, 183:394-405. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/s0014-4886(03)00180-8.
5. Sheng J.G., Jones R.A., Zhou X.Q., McGinness J.M., Van Eldik L.J., Mrak R.E., Griffin W.S. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for Tau protein phosphorylation. Neurochemistry International 2001, 39:341-348. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/s0197-0186(01)00041-9.
6. Feijoo C., Campbell D.G., Jakes R., Goedert M., Cuenda A. Evidence that phosphorylation of the microtubule-associated protein tau by SAPK4/p38δ at Thr50 promotes microtubule assembly. Journal of Cell Science 2005, 118:397-408. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1242/jcs.01655.
7. Yoshida H., Goedert M. Sequential phosphorylation of Tau protein by cAMP-dependent protein kinase and SAPK4/p38 delta or JNK2 in the presence of heparin generates the AT100 epitope. Journal of Neurochemistry 2006, 99:154-164. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1471-4159.2006.04052.x.
8. Zhu X.M., Rottkamp C.A., Boux H.P., Takeda A.P., Perry G.P., Smith M.A.P. Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2000, 59:880-888. http://www.ncbi.nlm.nih.gov/pubmed/.
9. Kelleher I., Garwood C., Hanger D.P., Anderton B.H., Noble W. Kinase activities increase during the development of tauopathy in htau mice. Journal of Neurochemistry 2007, 103:2256-2267. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1471-4159.2007.04930.x.
10. Lloret A., Badía M.C., Mora N.J., Ortega A., Pallardó F.V., Alonso M.D., Atamna H., Viña J. Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. Free Radical Biology & Medicine 2008, 44:2019-2025. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.freeradbiomed.2008.02.017.
11. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., Cobb M.H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine Reviews 2001, 22:153-183. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1210/er.22.2.153.
12. Mudher A., Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands?. Trends in Neurosciences 2002, 25:22-26. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/s0166-2236(00)02031-2.
13. Butterfield D.A., Yatin S.M., Varadarajan S., Koppal T. Amyloid beta-peptide-associated free radical oxidative stress, neurotoxicity, and Alzheimer's disease. Methods in Enzymology 1999, 309:746-768. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/s0076-6879(99)09050-3.
14. Cardoso S.M., Santana I., Swerdlow R.H., Oliveira C.R. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. Journal of Neurochemistry 2004, 89:1417-1426. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1111/j.1471-4159.2004.02438.x.
15. Ermak G., Harris C.D., Davies K.J.A. The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxidative stress. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2002, 16:814-824. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1096/fj.01-0846com.
16. Lloret A., Badia M.C., Giraldo E., Ermak G., Alonso M.D., Pallardó F.V., Davies K.J., Viña J. Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. Journal of Alzheimer's Disease 2011, 27:701-709. http://www.ncbi.nlm.nih.gov/pubmed/.
17. Pearson R.C., Esiri M.M., Hiorns R.W., Wilcock G.K., Powell T.P. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:4531-4534. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1073/pnas.82.13.4531.
18. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease Cooperative Study. New England Journal of Medicine 1997, 336:1216-1222. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1056/nejm199704243361704.
19. Dysken M.W., Sano M., Asthana S., Vertrees J.E., Pallaki M., Llorente M., Love S., Schellenberg G.D., McCarten J.R., Malphurs J., Prieto S., Chen P., Loreck D.J., Trapp G., Bakshi R.S., Mintzer J.E., Heidebrink J.L., Vidal-Cardona A., Arroyo L.M., Cruz A.R., Zachariah S., Kowall N.W., Chopra M.P., Craft S., Thielke S., Turvey C.L., Woodman C., Monnell K.A., Gordon K., Tomaska J., Segal Y., Peduzzi P.N., Guarino P.D. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Journal of the American Medical Association 2014, 311:33-44. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1001/jama.2013.282834.
20. Farina, N., Isaac, M.G., Clark, A.R., Rusted, J., Tabet, N., Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database of Systematic Reviews, 11 (2012) CD002854, CD002854. Pubmed: . http://www.ncbi.nlm.nih.gov/pubmed/.
21. Tabet N., Birks J., Evans J.G., Orrel M., Spector A. Vitamin E for Alzheimer's disease. Cochrane Database of Systematic Reviews 2000, 4. CD002854.
22. Lloret A., Badía M.C., Mora N.J., Pallardó F.V., Alonso M.D., Viña J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. Journal of Alzheimer's Disease 2009, 17:143-149. http://www.ncbi.nlm.nih.gov/pubmed/, 10.3233/jad-2009-1033.
23. Bozaykut P., Karademir B., Yazgan B., Sozen E., Siow R.C., Mann G.E., Ozer N.K. Effects of vitamin E on peroxisome proliferator-activated receptor γ and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia induced atherosclerosis. Free Radical Biology & Medicine 2014, http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.freeradbiomed.2014.02.017.
24. Testa G., Gamba P., Di Scipio F., Sprio A.E., Salamone P., Gargiulo S., Sottero B., Biasi F., Berta G.N., Poli G., Leonarduzzi G. Potentiation of amyloid-β peptide neurotoxicity in human dental-pulp neuron-like cells by the membrane lipid peroxidation product 4-hydroxynonenal. Free Radical Biology & Medicine 2012, 53:1708-1717. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.freeradbiomed.2012.08.581.
25. Dolado I., Swat A., Ajenjo N., De Vita G., Cuadrado A., Nebreda A.R. p38α MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007, 11:191-205. http://www.ncbi.nlm.nih.gov/pubmed/, 10.1016/j.ccr.2006.12.013.